1
|
Wang WL, Wu XY, Luo XY, Tang YQ, Cui J, Huang XY, Jiang YC, Liu Y, Li LM. Immunosuppressive alkaloids from Narcissus tazetta subsp. Chinensis and the mechanism of (+)-narciclasine in vitro and in vivo. PHYTOCHEMISTRY 2024; 225:114198. [PMID: 38936528 DOI: 10.1016/j.phytochem.2024.114198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 06/23/2024] [Accepted: 06/24/2024] [Indexed: 06/29/2024]
Abstract
Three previously undescribed and sixteen known alkaloids were bioguidedly isolated from the bulbs of Narcissus tazetta subsp. chinensis (M.Roem.) Masamura & Yanagih. The structures were elucidated by spectroscopic data, including HRESIMS, NMR, and ECD. Eleven of the isolated alkaloids exhibited immunosuppressive activity on the proliferation of human T cells. (+)-Narciclasine (18) showed the most significantly suppressive activity with an IC50 value of 14 ± 5 nM. In vitro, (+)-narciclasine (18) blocked NF-κB signal transduction, but did not affect PI3K/AKT signal transduction. What was more, (+)-narciclasine significantly reduced ALT and AST levels and alleviated liver damage induced by ConA in AIH mouse model.
Collapse
Affiliation(s)
- Wen-Ling Wang
- College of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China; Research Center, Chengdu Medical College, Chengdu, 610500, China
| | - Xiu-Yin Wu
- Research Center, Chengdu Medical College, Chengdu, 610500, China
| | - Xing-Yan Luo
- Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China; Research Center, Chengdu Medical College, Chengdu, 610500, China
| | - Yu-Qin Tang
- Research Center, Chengdu Medical College, Chengdu, 610500, China
| | - Jia Cui
- College of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China
| | - Xin-Yue Huang
- College of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China
| | - Yu-Chen Jiang
- College of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China
| | - Yang Liu
- Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China; Research Center, Chengdu Medical College, Chengdu, 610500, China.
| | - Li-Mei Li
- College of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China.
| |
Collapse
|
2
|
Zhang T, Luo X, Jing L, Mo C, Guo H, Yang S, Wang Y, Zhao K, Lai Y, Liu Y. Toosendanin inhibits T-cell proliferation through the P38 MAPK signalling pathway. Eur J Pharmacol 2024; 973:176562. [PMID: 38588767 DOI: 10.1016/j.ejphar.2024.176562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2024] [Revised: 03/20/2024] [Accepted: 04/03/2024] [Indexed: 04/10/2024]
Abstract
In recent years, immunosuppressants have shown significant success in the treatment of autoimmune diseases. Therefore, there is an urgent need to develop additional immunosuppressants that offer more options for patients. Toosendanin has been shown to have immunosuppressive activity in vitro as well as effects on autoimmune hepatitis (AIH) in vivo. Toosendanin did not induce apoptosis in activated T-cells and affect the survival rate of naive T-cells. Toosendanin did not affect the expression of CD25 or secretion of IL-2 by activated T-cells, and not affect the expression of IL-4 and INF-γ. Toosendanin did not affect the phosphorylation of STAT5, ERK, AKT, P70S6K. However, toosendanin inhibited proliferation of anti-CD3/anti-CD28 mAbs-activated T-cells with IC50 of (10 ± 2.02) nM. Toosendanin arrested the cell cycle in the G0/G1 phase, significantly inhibited IL-6 and IL-17A secretion, promoted IL-10 expression, and inhibited the P38 MAPK pathway. Finally, toosendanin significantly alleviated ConA-induced AIH in mice. In Summary, toosendanin exhibited immunosuppressive activity in vivo and in vitro. Toosendanin inhibits the proliferation of activated T-cells through the P38 MAPK signalling pathway, significantly suppresses the expression of inflammatory factors, enhances the expression of anti-inflammatory factors, and effectively alleviates ConA-induced AIH in mice, suggesting that toosendanin may be a lead compound for the development of novel immunomodulatory agents with improved efficacy and reduced toxicity.
Collapse
Affiliation(s)
- Ting Zhang
- Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China; School of Pharmacy, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China
| | - Xingyan Luo
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China; Development and Regeneration Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China
| | - Lin Jing
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, 530004, Guangxi, People's Republic of China
| | - Chunfen Mo
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China
| | - Huijie Guo
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China
| | - Shuxia Yang
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China
| | - Yantang Wang
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China
| | - Ketian Zhao
- School of Pharmacy, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China; Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China
| | - Yi Lai
- School of Laboratory Medicine, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China.
| | - Yang Liu
- Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China; School of Pharmacy, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China; Development and Regeneration Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, 610500, Sichuan, People's Republic of China.
| |
Collapse
|
3
|
Liu Y, Li X, Wu X, Luo X, Yan B, Mo C, Guo H, Yang S, Wang Y, Lai Y, Puno P, Li L. Sis-25, a meroditerpenoid derivative with a cyclobutane scaffold, inhibits activated T cell proliferation by targeting GSK3β in vitro and in vivo. Eur J Pharmacol 2022; 929:175151. [PMID: 35841942 DOI: 10.1016/j.ejphar.2022.175151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 07/03/2022] [Accepted: 07/07/2022] [Indexed: 11/03/2022]
Abstract
A series of novel scopariusicide derivatives were designed and synthesized starting from the main diterpenoid from the aerial parts of Isodon scoparius. Sis-25 was the most effective compound among them. The potential mechanism(s) of its immunosuppressive activity in vitro, as well as its effects on delayed type hypersensitivity (DTH) reaction and imiquimod-induced dermatitis in vivo were investigated in this study. Sis-25 inhibited anti-CD3/anti-CD28 mAbs, PHA or alloantigen-induced T cell proliferation without obvious cytotoxicity. Sis-25 was a highly selective inhibitor of GSK3-β and inhibited the mTOR/p70S6K pathway but not the PI3K/Akt, p38 MAPK/ERK 1/2 and JAK3/STAT5 pathways. Furthermore, Sis-25 significantly inhibited IFN-γ, IL-6 and IL-17 expression but not IL-10 expression in activated T cells. Finally, Sis-25 treatment mitigated the DNFB-induced DTH reaction and ameliorated imiquimod-induced dermatitis. In summary, Sis-25 exerted significant immunosuppressive activity by targeting GSK3β in vitro and in vivo. Sis-25 may guide the design of new drugs for more effective and safer treatments of autoimmune diseases and provide new insight into developing utilizations of Isodon scoparius.
Collapse
Affiliation(s)
- Yang Liu
- Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan, PR China; Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, PR China
| | - Xingren Li
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, PR China
| | - Xiuyin Wu
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, PR China
| | - Xingyan Luo
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, PR China
| | - Bingchao Yan
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, PR China
| | - Chunfen Mo
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, PR China
| | - Huijie Guo
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, PR China
| | - Shuxia Yang
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, PR China
| | - Yantang Wang
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, PR China
| | - Yi Lai
- Research Center, Chengdu Medical College, Chengdu, 610500, Sichuan, PR China
| | - Pematenzin Puno
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, PR China.
| | - Limei Li
- College of Pharmacy, Southwest Minzu University, Chengdu, 610225, Sichuan, PR China.
| |
Collapse
|
4
|
Ayoub R, Jilani J, Jarrar Q, Alani R, Ardianto C, Goh KW, Ali D, Moshawih S. Synthesis and In-Vivo Evaluation of Benzoxazole Derivatives as Promising Anti-Psoriatic Drugs for Clinical Use. Molecules 2022; 27:3023. [PMID: 35566373 PMCID: PMC9104975 DOI: 10.3390/molecules27093023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 05/03/2022] [Accepted: 05/05/2022] [Indexed: 02/04/2023] Open
Abstract
2-(4-Chlorophenyl)-5-benzoxazoleacetic acid (CBA) and its ester, methyl-2-(4-chloro-phenyl)-5-benzoxazoleacetate (MCBA), were synthesized, and their structures were confirmed by 1HNMR, IR, and mass spectrophotometry. The anti-psoriatic activities of CBA and MCBA were tested using an imiquimod (IMQ)-induced psoriatic mouse model, in which mice were treated both topically (1% w/w) and orally (125 mg/kg) for 14 days. The erythema intensity, thickness, and desquamation of psoriasis were scored by calculating the psoriasis area severity index (PASI). The study also included the determination of histopathological alterations in the skin tissues of treated mice. Topical and oral administration of CBA and MCBA led to a reduction in erythema intensity, thickness, and desquamation, which was demonstrated by a significant decrease in the PASI value. In addition, skin tissues of mice treated with CBA and MCBA showed less evidence of psoriatic alterations, such as hyperkeratosis, parakeratosis, scale crust, edema, psoriasiform, and hyperplasia. After administration of either topical or oral dosing, the anti-psoriatic effects were found to be stronger in MCBA-treated than in CBA-treated mice. These effects were comparable to those produced by Clobetasol propionate, the reference drug. This drug discovery could be translated into a potential new drug for future clinical use in psoriasis treatment.
Collapse
Affiliation(s)
- Rami Ayoub
- Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan;
| | - Jamal Jilani
- Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan;
| | - Qais Jarrar
- Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan;
| | - Raad Alani
- Department of Physiotherapy, Faculty of Allied Medical Sciences, Isra University, Amman 11622, Jordan; (R.A.); (D.A.)
| | - Chrismawan Ardianto
- Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia
| | - Khang Wen Goh
- Faculty of Data Science and Information Technology, INTI International University, Nilai 71800, Malaysia
| | - Dalia Ali
- Department of Physiotherapy, Faculty of Allied Medical Sciences, Isra University, Amman 11622, Jordan; (R.A.); (D.A.)
| | - Said Moshawih
- PAP Rashidah Sa’adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Gadong BE1410, Brunei;
| |
Collapse
|
5
|
Lai Y, Luo XY, Guo HJ, Wang SY, Xiong J, Yang SX, Li LM, Zou Q, Mo CF, Wang YT, Liu Y. PO-322 exerts potent immunosuppressive effects in vitro and in vivo by selectively inhibiting SGK1 activity. Br J Pharmacol 2020; 177:1666-1676. [PMID: 31724152 DOI: 10.1111/bph.14926] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Revised: 09/14/2019] [Accepted: 10/29/2019] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND AND PURPOSE Immunosuppressive drugs have shown great promise in treating autoimmune diseases in recent years. A series of novel oxazole derivatives were screened for their immunosuppressive activity. PO-322 [1H-indole-2,3-dione 3-(1,3-benzoxazol-2-ylhydrazone)] was identified as the most effective of these compounds. Here, we have investigated the mechanism(s) underlying the inhibition of T-cell proliferation in vitro by PO-322, as well as its effects on the delayed-type hypersensitivity (DTH) response and imiquimod-induced dermatitis in vivo. EXPERIMENTAL APPROACH T-cell proliferation and apoptosis were analysed with flow cytometry. Cell viability was assessed with a CCK-8 assay. Protein kinase activity was assessed by SelectScreen Kinase Profiling Services. The phosphorylation of signal-regulated molecules was measured by Western blot. Cytokine levels were determined by elisa. The effect of PO-322 on DTH and imiquimod-induced dermatitis was evaluated in BALB/c mice. KEY RESULTS PO-322 inhibited human T-cell proliferation with anti-CD3/anti-CD28 mAbs or alloantigen without significant cytotoxicity. Importantly, PO-322 was a selective inhibitor of the serum- and glucocorticoid-regulated kinase 1 (SGK1) and decreased NDRG1 phosphorylation but not p70S6K, STAT5, Akt, or ERK1/2 phosphorylation. Furthermore, PO-322 inhibited IFN-γ, IL-6, and IL-17 expression but not IL-10 expression. Finally, treatment with PO-322 was safe and effective for ameliorating the DTH response and imiquimod-induced dermatitis in mice. CONCLUSIONS AND IMPLICATIONS PO-322 exerted immunosuppressive activity in vitro and in vivo by selectively inhibiting SGK1 activity. PO-322 represents a potential lead compound for the design and development of new drugs for the treatment of autoimmune diseases.
Collapse
Affiliation(s)
- Yi Lai
- School of Laboratory Medicine, Chengdu Medical College, Chengdu, China
| | - Xing-Yan Luo
- Research Center, Chengdu Medical College, Chengdu, China
| | - Hui-Jie Guo
- Research Center, Chengdu Medical College, Chengdu, China
| | - Si-Yu Wang
- Research Center, Chengdu Medical College, Chengdu, China
| | - Jing Xiong
- Research Center, Chengdu Medical College, Chengdu, China
| | - Shu-Xia Yang
- Research Center, Chengdu Medical College, Chengdu, China
| | - Li-Mei Li
- Research Center, Chengdu Medical College, Chengdu, China
| | - Qiang Zou
- Research Center, Chengdu Medical College, Chengdu, China
| | - Chun-Fen Mo
- Research Center, Chengdu Medical College, Chengdu, China
| | - Yan-Tang Wang
- Research Center, Chengdu Medical College, Chengdu, China.,Development and Regeneration Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, China
| | - Yang Liu
- Research Center, Chengdu Medical College, Chengdu, China.,Development and Regeneration Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, China
| |
Collapse
|